CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference

Leronlimab-mediated CCR5 blockade modulates T-Cell exhaustion pathways and PD-L1 Biology relevant to ICI responseDurable Clinical Observations ...
The Scientist

A Novel CCR5 Antagonist for Multiple Therapeutic Applications

Jacob Lalezari of CytoDyn shares insights about CCR5-targeting therapy for cancer, including triple negative breast cancer and colorectal cancer.
Medscape

Role of CXCR4 in HIV Infection and its Potential as a Therapeutic Target

The chemokine receptors CCR5 and CXCR4 are the two major coreceptors for HIV entry. Numerous efforts have been made to develop a new class of anti-HIV agents that target these coreceptors as an ...
Medscape

Maraviroc: A Coreceptor CCR5 Antagonist for Management of HIV Infection

Am J Health Syst Pharm. 2009;66(8):715-726. Mechanism of action of maraviroc. Before fusion of the HIV viral envelope and host cell membrane can occur, an HIV glycoprotein complex consisting of ...
Business Insider

CytoDyn Announces Vyrologix as Proprietary Name for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients in the United States

VANCOUVER, Washington, April 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 ...